Use of Ceftaroline in Complicated Methicillin-Resistant Staphylococcus aureus BacteremiaZainah, Hadeel MD; Vazquez, Jose A. MDInfectious Diseases in Clinical Practice: January 2013 - Volume 21 - Issue 1 - p 58–60 doi: 10.1097/IPC.0b013e3182602205 Case Reports Abstract Author Information Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia. From the Henry Ford Hospital, Detroit, MI. Correspondence to: Jose A. Vazquez, MD, Henry Ford Hospital, 2799 W Grand Blvd, CFP 202, Detroit, MI 48202. E-mail: email@example.com. J Vazquez is with the speakers’ bureaus of Pfizer, Astellas, Forest, and Merck. He has received grants from Merck and Astellas. H Zainah has no funding or conflicts of interest to disclose. The authors have no funding to disclose. © 2013 Lippincott Williams & Wilkins, Inc.